By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PerkinElmer reported after the close of the market on Thursday that its revenues climbed almost 10 percent in the fourth quarter.

For the three months ended Jan. 2, the firm said revenues totaled $470 million, compared to $428.5 million for the year-ago period. It exceeded consensus Wall Street estimates of $461.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.